On April 10, 2019, the groundbreaking ceremony of the GenScript-Legend Commercial Production Center project was held in Zhenjiang. Shanghai Longyao Biotechnology Co., Ltd. participated in the groundbreaking ceremony as an important strategic partner to witness this exciting moment together.
groundbreaking ceremony
GenScript's planned commercial production center in Zhenjiang covers an area of 200 mu and a total construction area of about 150,000 m2. It will build a commercial production base that meets the requirements of cGMP in China, Europe and the United States for antibody products, cell therapy and genes. Commercial production of therapeutics, thereby accelerating the entire process of biopharmaceuticals from concept to commercial production.
GenScript Zhenjiang Commercial Production Center Planning
Dr. David He, Vice President of Legend Bioproduction, said in his speech: As a "live" drug, cell therapy products have higher requirements than traditional pharmaceuticals in all aspects of production. The production of high-quality plasmids and viral vectors that meet the requirements of cGMP is a and a key link in the commercial production of gene therapy. GenScript CDMO has officially signed a memorandum of cooperation with Merck, the world's leading technology company, to jointly establish a strategic alliance focusing on plasmid and viral vector production. We believe that the early completion and commissioning of Legend Bio's cell therapy commercial production base and GenScript's CDMO commercial production base will accelerate the rapid development of the biopharmaceutical and cell therapy industries in China and the world, and create more value for customers and patients.
Dr. David He delivering a speech
Dr. Brian Hosung Min, CEO of GenScript's Biopharmaceutical Division, said in his speech, "At present, the field of gene and cell therapy at home and abroad is developing rapidly, but there are great challenges in large-scale production and quality control, and the establishment of regulatory requirements for biopharmaceuticals With huge investment in factories and high technical and industry barriers, the demand for CDMO services has risen rapidly. We believe that our efforts will strengthen China's advantages in the development of biological products and accelerate the development of the entire pharmaceutical industry."
Photo of Dr. Brian Hosung Min delivering a speech
Ye Shengqin, chairman of Longyao Biotechnology, attended the groundbreaking ceremony and delivered a congratulatory speech.
Ye Shengqin, Chairman of Longyao Biotechnology
Chairman Ye Shengqin said: Longyao Biology and GenScript have signed a strategic cooperation agreement, and cooperation is the main theme of the development of innovative enterprises. GenScript not only has a deep understanding of CDE rules in product declaration, but also has a complete solution for product declaration strategy. Make the project, do it well, do it fast!
Chairman Ye Shengqin introduced: Shanghai Longyao Biotechnology Co., Ltd. is a national high-tech enterprise invested and held by China Biotechnology Service Holdings Co., Ltd. It is a company dedicated to the research and development and registration of tumor immune cell products. The company's advantage lies in the original research of products. The company's team of scientists is of international level. We have now completed the development of 12 product production pipelines, including immune effector cell products, immune activation cell products, and immune regulatory cell products, all of which have core technologies. Domestic and international patents, the two CAR-T products entrusted to GenScript's CDMO have unique advantages in the technical route. Longyao Bio's CAR-T-OX40 product is based on the traditional CAR-T structure with the addition of OX40 costimulatory molecules, which greatly improves the expansion ability of cells in vitro and in vivo, tumor killing ability, and reduces cell apoptosis. , the survival time in vivo is longer, and the therapeutic dose is reduced; Longyao Bio’s universal UCAR-T products break through the bottleneck of industrialized large-scale production, reduce costs, and improve the convenience of application; the preliminary verification of the clinical research results of the exploration of the two products safety and effectiveness. Longyao Bio plans to gradually start the new product registration application while completing the IND of the first two products. According to the company's development orientation, entrusting the professional plasmid virus vector platform CDMO cooperation is the development strategy of Longyao Bio, and I look forward to working with Kings Rui has a deeper and broader cooperation.
Delegates take a group photo